Le Lézard
Classified in: Health, Science and technology
Subject: Award

SEQENS North America Picks up Six 2019 Life Science CMO Leaderships Awards


SEQENS North America (formerly PCI Synthesis, Inc.), a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that it has won six 2019 Life Science Leader CMO Leadership Awards. The company won in every category: Quality, Capabilities, Compatibility, Expertise, Reliability, and Service across all three groups of respondents (Big Pharma, Small Pharma and Overall (combined Big and Small Pharma).

This is the fifth time in the CMO Leadership Awards program's eighth year that SEQENS has been awarded multiple awards, including across all six major categories. The company has now won 30 CMO Leadership Awards since 2014. The awards will be presented at The CMO Leadership Awards Reception at Convene, at 237 Park Avenue on March 20, 2019 in NYC.

For the 2019 CMO Leadership Awards, Life Science Leader magazine teamed up with Industry Standard Research (ISR) to determine the award recipients. More than 120 contract manufactures were assessed by 23 performance metrics in ISR's annual Contract Manufacturing Quality Benchmarking survey. Survey participants were recruited from Pharma and Biopharma companies of all sizes and were screened for decision-making influence related to working with contract manufacturing suppliers. Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months. This level of qualification ensures that survey responses are based on actual involvement with contract manufacturers and clear experiential data.

"Each year, the value that CMOs bring to individual biotech and pharma companies increases, as does the overall importance of the service sector to our entire and global drug development and manufacturing industry," said Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma.

"Amid growing industry competition, the fact that SEQENS North America continues to win CMO Leadership Awards, especially across all categories, is a testament to our people, training and equipment as well as to our results-driven culture ? particularly since winners are based on input from people who work with us," said Ed Price, president and CEO of SEQENS North America. "While we're now known as SEQENS North America, part of a global CDMO that can offer more resources and even deeper expertise, our commitment to being responsive to our sponsors remains a core value."

SEQENS North America, which provides small and mid-sized companies with the expertise to manufacture complex small molecules to be used as APIs, has a portfolio of commercially approved products that now includes nine commercial products that either have or are imminently receiving FDA approval for sale in the U.S. The division has more than 17 API and other advanced materials products in its pipeline.

About SEQENS North America
SEQENS North America (formerly PCI Synthesis) is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, Mass., a division of SEQENS, an integrated global leader in pharmaceutical synthesis and specialty ingredients with 24 manufacturing sites and 3 R&D centers in Europe, North America and Asia.

SEQENS North America is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a CDMO, SEQENS North America provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about SEQENS North America, its proprietary NCE development activities and process R&D capabilities please visit www.seqens.com.


These press releases may also interest you

at 11:45
SummaryProduct: Henna cones Issue: Chemical hazard / Product safety What to do: Stop using and selling them immediately and dispose of them in regular household garbage Who this is for: General public / Industry; Retail, Importers IssueHealth Canada...

at 11:30
The "Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033" report has been added to  ResearchAndMarkets.com's offering. The global...

at 11:30
XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid...

at 11:25
Manifest Technologies, Inc., developer of an AI-powered computational neuro-imaging platform for CNS disease, today unveiled the company after completing its initial funding and partnership with a top five global pharmaceutical company. Today, over...

at 11:08
Sunwave Health, a leader in healthcare technology, proudly announces the launch of MARA, a patent-pending, innovative AI Agent designed to transform the landscape of behavioral health documentation. Since its launch on October 25, 2023, MARA has...

at 11:04
MelliCell Inc. has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $275,000 to conduct research and development (R&D) work on "Industrial Scale Technology for Drug Development in Mature Human...



News published on and distributed by: